Clinical Data, Inc. to Present at the 22nd Annual Piper Jaffray Health Care Conference

NEWTON, Mass.--(BUSINESS WIRE)-- Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a Company overview at the 22nd Annual Piper Jaffray Health Care Conference, November 30, 2010 at the New York Palace Hotel, New York, NY. Clinical Data’s presentation will take place at 2:00 p.m. EST.

A live audio and archived webcast of the Company’s presentation can be accessed through Clinical Data's website at www.clda.com.

About Clinical Data, Inc.

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in major therapeutic areas including oncology and inflammatory diseases. Clinical Data plans to differentiate its therapeutics by combining its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability, improving patient health and reducing costs. To learn more, please visit the Company's website at www.clda.com.



CONTACT:

Clinical Data, Inc.
Theresa McNeely, 617-467-6673
Vice President
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.